Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer

• Published in: The FEBS journal Vol. 281; no. 9; pp. 2172 - 2189
• Main Authors: Shaughnessy, Ronan, Retamal, Claudio, Oyanadel, Claudia, Norambuena, Andrés, López, Alejandro, Bravo‐Zehnder, Marcela, Montecino, Fabian J., Metz, Claudia, Soza, Andrea, González, Alfonso
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2014
• Subjects: apoptosis; Cancer; Cell growth; Desipramine - pharmacology; EGFR; Endocytosis; Endosomes - drug effects; Endosomes - metabolism; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Epidermal growth factor; HeLa Cells; Humans; Kinases; Ligands; Neoplasms - drug therapy; Phosphatidate Phosphatase - antagonists & inhibitors; phosphatidic acid; Phosphorylation; Propranolol - pharmacology; Receptor, Epidermal Growth Factor - metabolism; apoptosis; endocytosis; cancer; phosphatidic acid; EGFR
• ISSN: 1742-464X; 1742-4658
• DOI: 10.1111/febs.12770

Epidermal growth factor receptor (EGFR) exaggerated (oncogenic) function is currently targeted in cancer treatment with drugs that block receptor ligand binding or tyrosine kinase activity. Because endocytic trafficking is a crucial regulator of EGFR function, its pharmacological perturbation might provide a new anti‐tumoral strategy. Inhibition of phosphatidic acid (PA) phosphohydrolase (PAP) activity has been shown to trigger PA signaling towards type 4 phosphodiesterase (PDE4) activation and protein kinase A inhibition, leading to internalization of empty/inactive EGFR. Here, we used propranolol, its l‐ and d‐ isomers and desipramine as PAP inhibitors to further explore the effects of PAP inhibition on EGFR endocytic trafficking and its consequences on EGFR‐dependent cancer cell line models. PAP inhibition not only made EGFR inaccessible to stimuli but also prolonged the signaling lifetime of ligand‐activated EGFR in recycling endosomes. Strikingly, such endocytic perturbations applied in acute/intermittent PAP inhibitor treatments selectively impaired cell proliferation/viability sustained by an exaggerated EGFR function. Phospholipase D inhibition with FIPI (5‐fluoro‐2‐indolyl des‐chlorohalopemide) and PDE4 inhibition with rolipram abrogated both the anti‐tumoral and endocytic effects of PAP inhibition. Prolonged treatments with a low concentration of PAP inhibitors, although without detectable endocytic effects, still counteracted cell proliferation, induced apoptosis and decreased anchorage‐independent growth of cells bearing EGFR oncogenic influences. Overall, our results show that PAP inhibitors can counteract EGFR oncogenic traits, including receptor overexpression or activating mutations resistant to current tyrosine kinase inhibitors, perturbing EGFR endocytic trafficking and perhaps other as yet unknown processes, depending on treatment conditions. This puts PAP activity forward as a new suitable target against EGFR‐driven malignancy. Inhibition of phosphatidate phosphohydrolase (PAP) with propranolol (Prop) triggers a PA/PDE4/PKA pathway that induces endocytosis of empty/inactive EGFR, prolongs signaling lifetime of ligand‐activated EGFR in recycling endosomes and impairs EGFR‐driven cell proliferation/viability, unless PLD is inhibited with FIPI or endocytosis is abrogated with the PDE4 inhibitor rolipram. PAP is a new suitable target against oncogenic EGFR, operating upon endocytic pathways.